Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

AKUS


Top 10 Correlated ETFs

AKUS


Top 10 Correlated Stocks

AKUS


In the News

07:00 13 Aug 2022 AKUS

Akouos to Present at Bank of America 2022 Healthcare Conference

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

07:00 13 Aug 2022 AKUS

Akouos to Participate in Upcoming March Virtual Investor Conferences

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:

07:00 13 Aug 2022 AKUS

Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.

07:00 13 Aug 2022 AKUS

Akouos to Present at Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

07:00 13 Aug 2022 AKUS

Akouos to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September:

02:58 13 Aug 2022 AKUS

Akouos' Hearing Loss Gene Therapy Poised To Receive Orphan Drug Tag In Europe

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on Akouos Inc's (NASDAQ: AKUS) application for orphan drug designation for AK-OTOF. AK-OTOF is a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.

07:00 13 Aug 2022 AKUS

Akouos to Present at Upcoming August Virtual Investor Conferences

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in August:

08:24 13 Aug 2022 AKUS

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice

07:00 13 Aug 2022 AKUS

Akouos Appoints Dr. Kathy Reape as Chief Development Officer

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos.

12:46 13 Aug 2022 AKUS

What Makes Akouos, Inc. (AKUS) a New Buy Stock

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Financial details

Company Rating
Neutral
Market Cap
110.46M
Income
-97.57M
Revenue
0
Book val./share
6.05
Cash/share
6.06
Dividend
-
Dividend %
-
Employees
103
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
-1.1
Forward P/E
-
PEG
-5.08
P/S
-
P/B
0.52
P/C
0.51
P/FCF
-1.43
Quick Ratio
11.27
Current Ratio
11.39
Debt / Equity
0.14
LT Debt / Equity
0.14
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
78.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
8.33%
-
-
-
-
SMA20
-21.93%
SMA50
3.55%
SMA100
-36.11%
Inst Own
100%
Inst Trans
1.48%
ROA
-38%
ROE
-40%
ROC
-0.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
34.63M
Shs Float
17.33M
-
-
-
-
Target Price
-
52W Range
2.315-13.69
52W High
-76%
52W Low
+56%
RSI
47.47
Rel Volume
0.25
Avg Volume
407.21K
Volume
100.51K
Perf Week
6.12%
Perf Month
-33.48%
Perf Quarter
-40.91%
Perf Half Y
-48.17%
-
-
-
-
Beta
0.338662
-
-
Volatility
0.19%, 0.42%
Prev Close
10.25%
Price
3.12
Change
9.47%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2020-12-31 2021-12-31
Revenue per share
00
Net income per share
-2.77-4.94
Operating cash flow per share
-2.32-3.63
Free cash flow per share
-2.58-4.15
Cash per share
17.5513.24
Book value per share
17.713.31
Tangible book value per share
17.713.31
Share holders equity per share
17.713.31
Interest debt per share
0.061.65
Market cap
279.41M100.22M
Enterprise value
211.59M7.28M
P/E ratio
-5.75-1.16
Price to sales ratio
00
POCF ratio
-6.85-1.57
PFCF ratio
-6.17-1.38
P/B Ratio
0.90.43
PTB ratio
0.90.43
EV to sales
00
Enterprise value over EBITDA
-4.53-0.09
EV to operating cash flow
-5.19-0.11
EV to free cash flow
-4.67-0.1
Earnings yield
-0.17-0.86
Free cash flow yield
-0.16-0.73
Debt to equity
00.12
Debt to assets
0.070.16
Net debt to EBITDA
1.451.12
Current ratio
29.0114.06
Interest coverage
00
Income quality
0.840.74
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
00
Research and developement to revenue
00
Intangibles to total assets
00
Capex to operating cash flow
0.110.14
Capex to revenue
00
Capex to depreciation
-2.08-2.41
Stock based compensation to revenue
00
Graham number
33.2138.46
ROIC
-0.15-0.33
Return on tangible assets
-0.15-0.31
Graham Net
16.2510.67
Working capital
299.93M219.36M
Tangible asset value
00
Net current asset value
287.9M191.06M
Invested capital
00.12
Average receivables
00
Average payables
895K1.09M
Average inventory
00
Days sales outstanding
00
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
00
Payables turnover
00
Inventory turnover
00
ROE
-0.16-0.37
Capex per share
-0.26-0.51

Quarterly Fundamentals Overview

Last date of statement is 2022-03-31 for Q1

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-03-31
Revenue per share
00000
Net income per share
-0.47-0.66-0.67-0.72-0.78
Operating cash flow per share
-0.46-0.35-0.57-0.46-0.58
Free cash flow per share
-0.58-0.42-0.63-0.49-0.66
Cash per share
3.433.827.256.746.06
Book value per share
8.668.057.446.786.05
Tangible book value per share
8.668.057.446.786.05
Share holders equity per share
8.668.057.446.786.05
Interest debt per share
0.540.830.830.840.85
Market cap
475.52M431.37M399.81M292.96M164.01M
Enterprise value
376.44M328.63M313.94M200.03M138.76M
P/E ratio
-7.39-4.74-4.36-2.94-1.52
Price to sales ratio
00000
POCF ratio
-29.87-35.68-20.21-18.38-8.18
PFCF ratio
-23.74-30.2-18.51-17.39-7.18
P/B Ratio
1.61.561.561.250.78
PTB ratio
1.61.561.561.250.78
EV to sales
00000
Enterprise value over EBITDA
-24.27-15.03-14.44-8.35-5.31
EV to operating cash flow
-23.64-27.18-15.87-12.55-6.92
EV to free cash flow
-18.79-23.01-14.54-11.88-6.07
Earnings yield
-0.03-0.05-0.06-0.09-0.16
Free cash flow yield
-0.04-0.03-0.05-0.06-0.14
Debt to equity
0.060.10.110.120.14
Debt to assets
0.080.130.140.160.18
Net debt to EBITDA
6.394.73.953.880.97
Current ratio
41.2422.6819.414.0611.39
Interest coverage
0000-105.19
Income quality
0.990.530.860.640.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.260.180.090.060.14
Capex to revenue
00000
Capex to depreciation
-6.42-2.4-1.56-0.88-3.03
Stock based compensation to revenue
00000
Graham number
9.5610.9410.5510.5110.32
ROIC
-0.05-0.07-0.08-0.1-0.11
Return on tangible assets
-0.05-0.07-0.08-0.09-0.11
Graham Net
6.45.726.055.444.7
Working capital
283.98M261.95M241.39M219.36M192.89M
Tangible asset value
00000
Net current asset value
265.98M233.97M213.27M191.06M164.48M
Invested capital
0.060.10.110.120.14
Average receivables
00000
Average payables
1.14M1.17M1.17M1.28M1.31M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.05-0.08-0.09-0.11-0.13
Capex per share
-0.12-0.06-0.05-0.03-0.08

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap